Coloplast is a defensive chronic-care compounder trading at a reset valuation after Kerecis reimbursement shocks, with its core ostomy and continence franchises still providing resilient growth, cash flow, and long-term recovery potential.
Overview
Coloplast is a high-quality global medtech leader in intimate chronic care, with dominant positions in ostomy, continence, wound, respiratory, and urology products. Its business is highly defensive because patients rely on recurring consumables that are clinically sensitive, non-discretionary, and difficult to switch. FY 2024/25 revenue reached DKK 27.9 billion, led by ostomy and continence care. Europe remains the anchor geography, while developed markets and emerging markets provide incremental growth. Superior skin-integrity outcomes, infection reduction, and patient loyalty underpin durable demand and strong retention.